A belinastatin eutectic and its preparation method and application
Through the formation of belistat and theophylline, the low water solubility and adverse injection reactions of belistat drugs are solved, the solubility and stability of the drug are improved, and the development of belistat oral preparations is realized. Simplify the production process and enhance the bioavailability of drugs.
Patent Information
- Application Number
- CN202211465525.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-22
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-11-22
AI Technical Summary
Due to its low water solubility and high permeability, belista drugs lead to adverse reactions during intravenous injection, and lack effective oral preparations, which affects patient compliance.
Develop a belistatheline eutectic eutectic, which forms a triacrylic eutectic by combining with theophylline at a molar ratio of 1:1 and using non-covalent bonds such as hydrogen bonds to form a triacrylic eutectic to improve the solubility of the drug and the physical and chemical stability of the drug. and adopts grinding and stirring preparation methods to simplify the process and are suitable for industrial production.
It improves the solubility and bioavailability of belista drugs, reduces adverse reactions in injections, enhances the stability of the drug and the development potential of oral preparations. It has simple process and mild conditions, and is suitable for large-scale production.
Smart Images

Figure CN115925708B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicines and relates to a belinophylline cocrystal and a preparation method and application thereof. Background Art
[0002] Belinostat is a histone deacetylase inhibitor (HDAC inhibitor) with a sulfonamide-hydroxamic acid amide structure. Its chemical name is: (2E)-N-hydroxy-3-[3-(benzenesulfonamide)phenyl]acrylic acid-2-amide. Belinostat is currently recognized in the international market as one of the best drugs for the treatment of T-cell lymphoma. The drug was first developed by a Danish pharmaceutical company and was granted orphan drug status by the FDA in 2009. In 2014, it was approved by the FDA for sale under the trade name of Belinostat was launched on the market, becoming the third drug approved for the treatment of rare and aggressive non-Hodgkin's lymphoma (NHL). Due to the unique hydroxamic acid functional group in its molecular structure, belinostat also plays an important role in the treatment of cancer, cardiovascular disease, HIV, Alzheimer's disease, malaria, allergic diseases, tuberculosis and other diseases, especially in combination with other anticancer drugs and / or radiotherapy.
[0003] According to the classification of the Biopharmaceutics Classification System (BCS), belinostat belongs to BCS Class II drugs, with a solubility in water of only 0.14 mg / mL (25°C), and has the properties of low solubility and high permeability. Belinostat lyophilized powder injection is mainly used for intravenous injection, and the U.S. Food and Drug Administration (FDA) recommends a dose of 1000 mg / m2. In order to maintain the drug concentration in the body, lyophilized powder injection will produce adverse reactions such as nausea, vomiting, fatigue, fever, anemia, and even lead to serious side effects including liver failure, thrombocytopenia, increased creatinine, gastrointestinal toxicity, pneumonia, tumor lysis syndrome, etc. Therefore, in order to improve the water solubility of the drug, reduce the adverse reactions caused by injection, and increase patient compliance, the development of oral preparations of belinostat has attracted the attention of many researchers.
[0004] Cocrystals are a new method for quickly and effectively improving the physicochemical properties of active pharmaceutical ingredients. The active pharmaceutical ingredients and cocrystal ligands are combined in the same crystal lattice through non-covalent bonds such as hydrogen bonds, van der Waals forces, π-π stacking, and halogen bonds. Without destroying the covalent bonds of the active pharmaceutical ingredients, the physiological activity of the drug is retained to the maximum extent, while the physicochemical properties of the drug are improved, the stability, solubility, dissolution and bioavailability of the drug are effectively improved, and potential application prospects are shown in the fields of pharmacology and biomedicine. At present, no belinostat cocrystal drugs and corresponding preparation methods have been disclosed. Summary of the invention
[0005] In order to solve the problems of poor patient compliance and low water solubility of the drug itself caused by belinostat injection, the present invention aims to provide a belinostat-theophylline cocrystal and a preparation method and application thereof. The belinostat-theophylline cocrystal provided by the present invention not only improves the solubility of belinostat drug, but also has high physicochemical stability, safe preparation process, small amount of solvent, good repeatability and mild conditions, which is conducive to industrial production and subsequent drug development, especially for the development of belinostat oral preparations.
[0006] One of the purposes of the present invention is to provide a belinostat theophylline co-crystal, wherein the belinostat theophylline co-crystal is formed by combining belinostat drug and theophylline in a molar ratio of 1:1;
[0007] The belinostatin eutectic is a triclinic system with a space group of The unit cell parameters are α=95.198(1)°,β=99.050(1)°,γ=95.056(1)°;the unit cell volume is Z=2.
[0008] Preferably, using Cu-Kα ray radiation, the X-ray powder diffraction pattern of the belinostatin theophylline cocrystal represented by a diffraction angle 2θ has characteristic diffraction peaks at 10.1±0.2°, 10.6±0.2°, 10.9±0.2°, 11.9±0.2°, 17.2±0.2°, 17.5±0.2°, 17.8±0.2°, 18.0±0.2°, 19.8±0.2°, 20.3±0.2°, and 20.9±0.2°;
[0009] Preferably, using Cu-Kα ray radiation, the X-ray powder diffraction pattern of the belinostatin theophylline cocrystal represented by a diffraction angle 2θ also has characteristic diffraction peaks at 5.3±0.2°, 12.9±0.2°, 13.9±0.2°, 15.6±0.2°, 16.0±0.2°, 16.5±0.2°, 20.9±0.2°, 22.1±0.2°, 22.4±0.2°, 22.8±0.2°, 23.3±0.2°, and 24.1±0.2°.
[0010] Preferably, the belinostatin co-crystal has a characteristic melting peak at 184±2°C.
[0011] As a preferred technical solution of the present invention, the second object of the present invention is to provide a method for preparing the belinophylline cocrystal as described in the first object, wherein the preparation method comprises the following method:
[0012] Belinostat drug and theophylline are mixed in a molar ratio of 1:(0.8-1.3), and ground under the action of an auxiliary solvent to obtain Belinostat theophylline cocrystal.
[0013] Preferably, the grinding is carried out in a ball mill or an agate mortar;
[0014] Preferably, the grinding frequency is 10-30 Hz, and the grinding time is 5-60 min.
[0015] Preferably, the auxiliary solvent comprises any one or a combination of at least two of an alcohol solvent, an ester solvent, a ketone solvent or a nitrile solvent, preferably any one or a combination of at least two of methanol, ethanol, isopropanol, acetone, acetonitrile or ethyl acetate;
[0016] Preferably, based on 1 g of belinostat, the amount of the auxiliary solvent added is 100-1500 μL;
[0017] Preferably, the preparation method further comprises drying the ground powder obtained after grinding, and the drying temperature is 10-40°C.
[0018] As another preferred technical solution of the present invention, the second object of the present invention is to provide a method for preparing belinophylline crystals, the preparation method comprising the following method:
[0019] Belinostat and theophylline are mixed in an organic solvent at a molar ratio of 1:(0.8-1.3) and reacted to obtain Belinostat theophylline cocrystal.
[0020] Preferably, the organic solvent comprises any one or a combination of at least two of an alcohol solvent, an ester solvent, a ketone solvent or a nitrile solvent, preferably any one or a combination of at least two of ethanol, isopropanol, acetone, acetonitrile or ethyl acetate;
[0021] Preferably, based on 1 g of belinostat, the amount of the auxiliary solvent added is 30-60 mL.
[0022] Preferably, the mixing and reacting are carried out under stirring conditions;
[0023] Preferably, the reaction temperature is 20-50°C and the reaction time is 12-48h;
[0024] Preferably, the preparation method further comprises sequentially performing solid-liquid separation and drying on the reactants obtained after the reaction;
[0025] Preferably, the solid-liquid separation method is filtration;
[0026] Preferably, the drying temperature is 10-40°C.
[0027] The third object of the present invention is to provide a use of the belinophylline cocrystal as described in the first object in the preparation of targeted drugs.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] The present invention synthesizes belinostat theophylline drug cocrystal for the first time. The cocrystal improves the stability and solubility of the drug without changing the covalent bonds of belinostat, thereby improving the efficacy and bioavailability, which is beneficial to the development of belinostat oral preparations.
[0030] The invention adopts a grinding and stirring preparation method to prepare the belinophylline cocrystal, which has simple process, mild conditions, good repeatability, is green and environmentally friendly, and is suitable for large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 The invention provides a powder X-ray diffraction pattern (PXRD) of the belinostatin cocrystal.
[0032] Figure 2 The crystal structure diagram of the belinostatin cocrystal provided by the present invention.
[0033] Figure 3 The invention provides a thermogravimetric analysis (TGA) and a differential scanning calorimetry (DSC) of the belinostatin cocrystal.
[0034] Figure 4 Comparison of long-term stability experimental spectra of belinostatin cocrystal provided by the present invention.
[0035] Figure 5 The present invention provides a powder dissolution curve of belinostat theophylline cocrystal and belinostat suspended for 6 hours in a phosphate buffer solution with a pH of 6.8. DETAILED DESCRIPTION
[0036] It should be noted that the following detailed descriptions are all exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs. The technical scheme of the present invention is further illustrated below by specific embodiments. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0037] Example 1
[0038] 31.8 mg of belinostat solid and 18.2 mg of theophylline solid were weighed and placed in a ball mill, 10 μL of isopropanol was added, and ball milling was performed at a frequency of 30 Hz for 10 min to obtain belinostat-theophylline cocrystal.
[0039] Example 2
[0040] 79.6 mg of Belinostat solid and 43.2 mg of theophylline solid were weighed and placed in a ball mill, 40 μL of ethyl acetate was added, and ball milling was performed at a frequency of 25 Hz for 15 min to obtain Belinostat-theophylline cocrystal.
[0041] Example 3
[0042] 31.8 mg of Belinostat solid and 18.2 mg of theophylline solid were weighed into an agate mortar, 10 μL of ethanol was added, and the mixture was ground for 8 min. After drying at room temperature, a solid sample of Belinostat-theophylline cocrystal was obtained.
[0043] Example 4
[0044] 31.8 mg of Belinostat solid and 18.2 mg of theophylline solid were weighed into an agate mortar, 20 μL of ethyl acetate was added, and the mixture was ground for 10 min. After drying at room temperature, a solid sample of Belinostat-theophylline cocrystal was obtained.
[0045] Example 5
[0046] At 30°C, 31.8 mg of belinostat solid, 18.2 mg of theophylline solid and 1 mL of ethyl acetate were added to a reaction bottle and stirred for 24 h. The resulting suspension was separated and dried at room temperature for 24 h. The resulting solid was the belinostat-theophylline cocrystal.
[0047] Example 6
[0048] At 25°C, 199 mg of belinostat solid, 112 mg of theophylline solid and 6 mL of acetonitrile were added to a reaction bottle and stirred for 48 h. The resulting suspension was separated and dried at room temperature for 12 h. The resulting solid was the belinostat-theophylline cocrystal.
[0049] The belinostat-theophylline cocrystal prepared in the embodiment of the present invention was characterized and its performance was measured. The specific method is as follows:
[0050] 1. Powder X-ray Diffraction
[0051] The PXRD patterns were measured at ambient temperature using an X-ray powder diffractometer Rigaku D / max 2500 (Rigaku, Japan). The measurement conditions were as follows: scanning range 3.5-40°, scanning rate 8° / min, scanning step length 0.02°, emission target Cu Kα, wavelength The voltage and current were 40 kV and 100 mA respectively.
[0052] The powder X-ray diffraction pattern of Belinostat-Theophylline cocrystal obtained in Example 5 of the present invention is as follows: Figure 1The X-ray powder diffraction patterns of belinostat-theophylline cocrystal were 5.3±0.2°, 10.1±0.2°, 10.6±0.2°, 10.9±0.2°, 11.9±0.2°, 12.9±0.2°, 13.9±0.2°, 15.6±0.2°, 16.0±0.2°, 16.5±0.2°, 17.2±0.2°, 17.5±0.2°, 17.8±0.2°, 18.0 There are characteristic peaks at ±0.2°, 19.8±0.2°, 20.3±0.2°, 20.9±0.2°, 22.1±0.2°, 22.4±0.2°, 22.8±0.2°, 23.3±0.2°, 24.1±0.2°, 24.7±0.2°, 25.7±0.2°, 26.8±0.2°, 27.3±0.2°, 27.7±0.2°, and 28.5±0.2°.
[0053] 2. Single crystal X-ray diffraction
[0054] Single crystal X-ray diffraction data - at 113K, using a Rigaku 007HF XtaLAB P200 diffractometer, using Mo Kα The CrystalClear program was used to integrate and restore the collected data, and SADABS was used for absorption correction. The OLEX2 direct method was used to solve the structure, and the SHELXL-97 program package was used to perform full matrix least squares optimization on F2 to determine the structure and spatial arrangement of atoms inside the crystal.
[0055] The eutectic prepared in the embodiment of the present invention (see Figure 2 ) belongs to the triclinic system, and the space group is One belinostat molecule and one theophylline molecule are bound together by hydrogen bonds, and the unit cell parameters are α=95.198(1)°,β=99.050(1)°,γ=95.056(1)°;the unit cell volume is Z=2.
[0056] 3. Differential Scanning Calorimetry
[0057] Differential Scanning Calorimetry (DSC) experiments were performed using a Mettler Toledo DSC 1 / 500. Samples (5-10 mg) were heated in a standard aluminum pan at a heating rate of 10°C / min under nitrogen.
[0058] The belinostat-theophylline cocrystal prepared in the embodiment of the present invention was subjected to DSC analysis (see Figure 3), the results showed that the belinostat-theophylline cocrystal had a sharp endothermic peak at 185°C, indicating that its melting point was about 185°C, and further indicating that this substance was a single crystalline phase.
[0059] 4. Thermogravimetric analysis (TGA)
[0060] TGA analysis was performed using a Mettler TGA / DSC 1stare system. A sample weighing 5-10 mg was placed in a standard alumina crucible and scanned at a heating rate of 10°C / min at a nitrogen flow rate of 20 mL / min.
[0061] The Belinostat-theophylline cocrystal prepared in the embodiment of the present invention was subjected to TGA analysis (see Figure 3 ), the results showed that its thermogravimetric curve began to lose weight at 185℃.
[0062] 5. Accelerated stability test
[0063] The stability of the cocrystal was tested at 75% relative humidity (RH). The cocrystal sample was weighed and stored in a desiccator filled with saturated sodium chloride solution to maintain humidity. The system was stored at 40°C and finally weighed and the PXRD pattern was determined.
[0064] PXRD spectrum (see Figure 4 ) The results showed that the sample had no significant changes after 180 days, proving that the belinostat-theophylline cocrystal had not undergone any transformation and had good stability.
[0065] 6. Dissolution Determination
[0066] The powder dissolution data of belinostat and belinostat-theophylline cocrystal were compared.
[0067] (1) The powder dissolution test method is as follows:
[0068] Powder dissolution test was performed on an RC-6 dissolution tester. Belinostat and cocrystal samples were sieved through a 80-100 mesh standard sieve to obtain samples with similar particle size ranges to be tested to reduce the effect of particle size on the experimental results. Belinostat and cocrystal drugs with a mass of 318 mg and 500 mg were added to a dissolution cup containing 300 mL of potassium dihydrogen phosphate buffer (pH = 6.8) preheated at 37°C for 1 h, with a paddle speed of 100 rpm. The temperature was 37°C. 2 mL of solution was taken out from the container at 1, 3, 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300 and 360 min, respectively, and filtered through a 0.45 mm nylon filter, and an equal volume of 37°C potassium dihydrogen phosphate buffer was added to the dissolution cup. The solution was appropriately diluted and the concentration of Belinostat in the solution was determined by high performance liquid chromatography. Each group of experiments was repeated 3 times to eliminate experimental errors. (2) Liquid phase conditions
[0069] Chromatographic column: Agilent Extend C18 column, 4.6 mm × 250 mm, 5 μm; column temperature: 30 ° C; mobile phase: 0.1% phosphoric acid aqueous solution and acetonitrile (60:40% v / v); flow rate: 1 mL / min; injection volume: 10 μL; wavelength: 272 nm.
[0070] Powder dissolution curve is attached Figure 5 The results showed that in a phosphate buffer solution of pH = 6.8, the belinostat-theophylline drug cocrystal provided by the present invention had a faster dissolution rate than the raw material belinostat, reaching a maximum apparent solubility in about 20 minutes, and a maximum concentration of about 0.35 mg / mL, which was 2.22 times that of single belinostat.
[0071] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.
Claims
1. A belinastatin cocrystal, characterized in that: The belinostat theophylline co-crystal is formed by combining belinostat drug and theophylline in a molar ratio of 1:1; The belinostatin eutectic is a triclinic system with a space group of The unit cell parameters are α=95.198(1)°,β=99.050(1)°,γ=95.056(1)°;the unit cell volume is Z=2.
2. The belinophylline cocrystal according to claim 1, characterized in that Using Cu-Kα ray radiation, the belinostatin theophylline cocrystal has an X-ray powder diffraction pattern represented by a diffraction angle 2θ at 10.1±0.2°, 10.6±0.2°, 10.9±0.2°, 11.9±0.2°, 17.2±0.2°, 17.5±0.2°, 17.8±0.2°, 18.0±0.2°, 19.8±0.2°, 20.3±0.2°, and 20.9±0.2°; Using Cu-Kα ray radiation, the X-ray powder diffraction pattern of the belinostatin theophylline co-crystal expressed by a diffraction angle 2θ also has characteristic diffraction peaks at 5.3±0.2°, 12.9±0.2°, 13.9±0.2°, 15.6±0.2°, 16.0±0.2°, 16.5±0.2°, 20.9±0.2°, 22.1±0.2°, 22.4±0.2°, 22.8±0.2°, 23.3±0.2°, and 24.1±0.2°.
3. The belinophylline cocrystal according to claim 1, characterized in that The belinostatin cocrystal has a characteristic melting peak at 184±2°C.
4. The method for preparing the belinophylline cocrystal according to any one of claims 1 to 3, characterized in that: The preparation method comprises the following method: The belinostat drug and theophylline are mixed in a molar ratio of 1:(0.8-1.3), and ground under the action of an auxiliary solvent to obtain belinostat theophylline cocrystal; The grinding is carried out in a ball mill or an agate mortar; The auxiliary solvent includes any one or a combination of at least two of an alcohol solvent, an ester solvent, a ketone solvent or a nitrile solvent, specifically any one or a combination of at least two of methanol, ethanol, isopropanol, acetone, acetonitrile or ethyl acetate; Based on the addition amount of belinostat being 1 g, the addition amount of the auxiliary solvent is 100-1500 μL.
5. The preparation method according to claim 4, characterized in that: The grinding frequency is 10-30 Hz, and the grinding time is 5-60 min.
6. The preparation method according to claim 4, characterized in that: Preferably, the preparation method further comprises drying the ground powder obtained after grinding, and the drying temperature is 10-40°C.
7. The method for preparing the belinophylline cocrystal according to any one of claims 1 to 3, characterized in that: The preparation method comprises the following method: The belinostat drug and theophylline are mixed in an organic solvent at a molar ratio of 1:(0.8-1.3), and reacted to obtain a belinostat theophylline cocrystal; The organic solvent includes any one or a combination of at least two of an alcohol solvent, an ester solvent, a ketone solvent or a nitrile solvent, specifically any one or a combination of at least two of ethanol, isopropanol, acetone, acetonitrile or ethyl acetate; The reaction temperature is 20-50°C, and the reaction time is 12-48h.
8. The preparation method according to claim 7, characterized in that: Based on the addition amount of belinostat being 1 g, the addition amount of the auxiliary solvent is 30-60 mL.
9. The preparation method according to claim 7, characterized in that: The mixing and reaction are carried out under stirring conditions.
10. The preparation method according to claim 7, characterized in that: The preparation method further comprises sequentially performing solid-liquid separation and drying on the reactants obtained after the reaction; The solid-liquid separation method is filtration; The drying temperature is 10-40°C.
